Literature DB >> 2956039

Reproducibility of the glucagon test.

S Arnold-Larsen, S Madsbad, C Kühl.   

Abstract

The influence of the fasting blood glucose (FBG) concentration on the beta-cell responsiveness to glucagon was studied twice in 9 insulin-dependent diabetic patients with residual beta-cell function. At a FBG of 7.7 +/- 0.3 mmol/l (mean +/- SEM) all patients displayed a preserved beta-cell function with a plasma C-peptide concentration of 0.25 +/- 0.03 nmol/l 6 min after an i.v. injection of glucagon. In contrast, at a FBG of 3.2 +/- 0.01 mmol/l 4 out of 9 patients would have been classified as not having an endogenous insulin secretion. All the patients had the lowest 6 min C-peptide concentration 0.06 +/- 0.01 nmol/l on the day with the lowest blood glucose concentration. The reproducibility of the glucagon test was assessed by comparing the results from two test days in 12 insulin-dependent, 9 non-insulin-dependent diabetic patients and 6 normal subjects. The 6 min plasma C-peptide concentration, the peak plasma C-peptide concentration, and the area under the plasma C-peptide curves were not different on the two test days in any subgroup. In all diabetic patients and normal subjects, the 6 min plasma C-peptide concentration (r = 0.93, coefficient of variation (CV) = 0.16), the peak plasma C-peptide concentration (r = 0.93, CV = 0.16) and the area under the plasma C-peptide curve (r = 0.94, CV = 0.16) were all significantly correlated. The results show that the prevailing FBG significantly affects the outcome of the glucagon test and confirm its reproducibility.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2956039     DOI: 10.1111/j.1464-5491.1987.tb00884.x

Source DB:  PubMed          Journal:  Diabet Med        ISSN: 0742-3071            Impact factor:   4.359


  3 in total

1.  Fasting plasma C-peptide, glucagon stimulated plasma C-peptide, and urinary C-peptide in relation to clinical type of diabetes.

Authors:  H J Gjessing; L E Matzen; O K Faber; A Frøland
Journal:  Diabetologia       Date:  1989-05       Impact factor: 10.122

2.  Islet cell antibodies are associated with beta-cell failure also in obese adult onset diabetic patients.

Authors:  A Gottsäter; M Landin-Olsson; A Lernmark; P Fernlund; G Sundkvist
Journal:  Acta Diabetol       Date:  1994-12       Impact factor: 4.280

3.  Lessons from the mixed-meal tolerance test: use of 90-minute and fasting C-peptide in pediatric diabetes.

Authors:  Rachel E J Besser; Beverley M Shields; Rosaura Casas; Andrew T Hattersley; Johnny Ludvigsson
Journal:  Diabetes Care       Date:  2012-10-30       Impact factor: 19.112

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.